Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for
Stroke Prevention and Recovery (ASPIRE)
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Study ID: 3759
NCT Number: NCT03907046
Principal Investigator: Farhan Siddiq, MD
Department: Surgery-Neurosurgery
Eligibility: Both men and women 18 years old to 100 years old. Does not accept healthy volunteers.
For questions about this study, please contact:
ClinicalTrialsInterest@health.missouri.edu(573) 882-7026